关键词: 结核, 免疫疗法, 总结性报告(主题)

Abstract:

The Global Tuberculosis Report 2022 showed a simultaneous increase of the numbers of people with tuberculosis disease, drug-resistant TB, or tuberculosis deaths in 2021, which had posed a serious challenge to the realization of the goal of End TB Strategy. Triple infections of TB/HIV/COVID-19 has hit heavily on the global TB control efforts. Therefore, It’s still a long way for us to achieve the global goal of ending TB as scheduled. Novel changes of the global tuberculosis epidemic situation constitutes new challenges for the management of tuberculosis. Although great progress has been made in shortening the course of treatment and improving the medication effectiveness for treating both drug-susceptible and drug-resistant tuberculosis, these new shorter all-oral treatment regimens still have not been rolled out globally, the adverse reactions of the first-line and second-line anti-tuberculosis drugs are still relatively high, while the immunotherapy for tuberculosis may provide a new opportunity for the current dilemma of chemotherapy. Thus, we tried to interpret the key points of the Expert Consensus on Immunotherapy for Tuberculosis (2022 edition) with the hope that it may play a positive role in increasing the treatment success rate of tuberculosis therapy.

Key words: Tuberculosis, Immunotherapy, Consensus development conferences as topic